Effectiveness of hepatitis B treatment in clinical practice

Gastroenterology

Volumn 142, Issue 6, 2012, Pages

  Scaglione, Steven J ^a   Lok, Anna S F ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Antiviral Therapy; Efficacy; Interferon; Nucleos(t)ide Analogues; Screening

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; AUTOIMMUNE DISEASE; BONE DENSITY; BONE MARROW SUPPRESSION; CLINICAL PRACTICE; CONSOLIDATION CHEMOTHERAPY; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FLU LIKE SYNDROME; GENETIC RESISTANCE; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY TUBULE DISORDER; LACTIC ACIDOSIS; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER TRANSPLANTATION; MONOTHERAPY; MOOD CHANGE; MYOPATHY; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS RESISTANCE;

EID: 84860304268     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2012.01.044     Document Type: Article

References (74)

1. A.E. Mitchell, H.M. Colvin, R. Palmer Beasley Institute of Medicine recommendations for the prevention and control of hepatitis B and C Hepatology 51 2010 729 733
2. A. Hatzakis, S. Wait, J. Bruix The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference J Viral Hepat 18 Suppl 1 2011 1 16
3. World Health Organization Hepatitis B vaccines Wkly Epidemiol Rec 79 2004 253 264
4. J.F. Perz, G.L. Armstrong, L.A. Farrington The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide J Hepatol 45 2006 529 538
5. G.N. Ioannou Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey Ann Intern Med 154 2011 319 328
6. CDC Screening for chronic hepatitis B among Asian/Pacific islander populations-New York City, 2005 Morb Mortal Wkly Rep 55 2006 505 509
7. G.K. Lau, T. Piratvisuth, K.X. Luo Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2005 2682 2695
8. P. Marcellin, G.K. Lau, F. Bonino Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 2004 1206 1217
9. H.L. Janssen, M. van Zonneveld, H. Senturk Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Lancet 365 2005 123 129
10. H.L. Chan, N.W. Leung, A.Y. Hui A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone Ann Intern Med 142 2005 240 250
11. J.L. Dienstag, E.R. Schiff, T.L. Wright Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 341 1999 1256 1263
12. P. Marcellin, T.T. Chang, S.G. Lim Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B N Engl J Med 348 2003 808 816
13. S.J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B N Engl J Med 352 2005 2673 2681
14. C.L. Lai, E. Gane, Y.F. Liaw Telbivudine versus lamivudine in patients with chronic hepatitis B N Engl J Med 357 2007 2576 2588
15. C.L. Lai, D. Shouval, A.S. Lok Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N Engl J Med 354 2006 1011 1020
16. T.T. Chang, R.G. Gish, R. de Man A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 2006 1001 1010
17. P. Marcellin, E.J. Heathcote, M. Buti Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2008 2442 2455
18. E.H. Buster, H.J. Flink, Y. Cakaloglu Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b Gastroenterology 135 2008 459 467
19. V.W. Wong, G.L. Wong, K.K. Yan Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B Hepatology 51 2010 1945 1953
20. P. Marcellin, F. Bonino, G.K. Lau Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a Gastroenterology 136 2009 2169 2179 e1-4
21. M. Zeng, Y. Mao, G. Yao A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B Hepatology 44 2006 108 116
22. J.L. Hou, D.Z. Xu, S. Guangeng Long-term telbivudine therapy with effective viral control results in resolution of liver fibrosis and inflammation achieving treatment goals in patients with chronic hepatitis B (abstr) Hepatology Suppl 2011 1048A
23. A.S. Lok, C.L. Lai, N. Leung Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 2003 1714 1722
24. P. Marcellin, T.T. Chang, S.G. Lim Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B Hepatology 48 2008 750 758
25. J. Heathcote Long term (4 year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (study 103) Hepatology 52 Suppl 2010 556A 557A
26. J.G. Reijnders, M.J. Perquin, N. Zhang Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B Gastroenterology 139 2010 491 498
27. H.W. Lee, H.J. Lee, J.S. Hwang Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B Hepatology 51 2010 415 421
28. S.J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B N Engl J Med 348 2003 800 807
29. S.J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years Gastroenterology 131 2006 1743 1751
30. C.L. Lai, R.N. Chien, N.W. Leung A one-year trial of lamivudine for chronic hepatitis B Asia Hepatitis Lamivudine Study Group N Engl J Med 339 1998 61 68
31. W.R. Kim, N.A. Terrault, R.A. Pedersen Trends in waiting list registration for liver transplantation for viral hepatitis in the United States Gastroenterology 137 2009 1680 1686
32. S.M. Lin, M.L. Yu, C.M. Lee Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma J Hepatol 46 2007 45 52
33. C. Niederau, T. Heintges, S. Lange Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B N Engl J Med 334 1996 1422 1427
34. Y.F. Yang, W. Zhao, Y.D. Zhong Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis J Viral Hepat 16 2009 265 271
35. J.J. Sung, K.K. Tsoi, V.W. Wong Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma Aliment Pharmacol Ther 28 2008 1067 1077
36. Y.F. Liaw, J.J. Sung, W.C. Chow Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521 1531
37. G.V. Papatheodoridis, P. Lampertico, S. Manolakopoulos Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review J Hepatol 53 2010 348 356
38. J.L. Dienstag, R.D. Goldin, E.J. Heathcote Histological outcome during long-term lamivudine therapy Gastroenterology 124 2003 105 117
39. T.T. Chang, Y.F. Liaw, S.S. Wu Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B Hepatology 52 2010 886 893
40. F. Bonino, P. Marcellin, G.K. Lau Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B Gut 56 2007 699 705
41. H.L. Chan, A. Thompson, M. Martinot-Peignoux Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report J Hepatol 55 2011 1121 1131
42. R.N. Chien, Y.F. Liaw, M. Atkins Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B Asian Hepatitis Lamivudine Trial Group Hepatology 30 1999 770 774
43. Y.F. Liaw, E. Gane, N. Leung 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B Gastroenterology 136 2009 486 495
44. C.M. Lange, J. Bojunga, W.P. Hofmann Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function Hepatology 50 2009 2001 2006
45. Y.F. Liaw, M. Raptopoulou-Gigi, H. Cheinquer Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study Hepatology 54 2011 91 100
46. Y.F. Liaw, I.S. Sheen, C.M. Lee Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease Hepatology 53 2011 62 72
47. A.S. Lok, B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
48. Y.F. Liaw, N. Leung, J.H. Kao Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update Hepatol Int 2 2008 263 283
49. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B J Hepatol 50 2009 227 242
50. U.H. Iloeje, H.I. Yang, J. Su Predicting cirrhosis risk based on the level of circulating hepatitis B viral load Gastroenterology 130 2006 678 686
51. M.W. Yu, S.H. Yeh, P.J. Chen Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men J Natl Cancer Inst 97 2005 265 272
52. C.J. Chen, H.I. Yang, J. Su Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 2006 65 73
53. C.F. Chen, W.C. Lee, H.I. Yang Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma Gastroenterology 141 2011 1240 1248 e2
54. T. Andreani, L. Serfaty, D. Mohand Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome Clin Gastroenterol Hepatol 5 2007 636 641
55. C.K. Hui, N. Leung, S.T. Yuen Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase Hepatology 46 2007 395 401
56. G. Zacharakis, J. Koskinas, S. Kotsiou The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(-) hepatitis B infection: association with liver disease progression A prospective cohort study J Hepatol 49 2008 884 891
57. M. Martinot-Peignoux, N. Boyer, M. Colombat Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers J Hepatol 36 2002 543 546
58. E.H. Buster, B.E. Hansen, G.K. Lau Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa Gastroenterology 137 2009 2002 2009
59. I.C. Wu, C.L. Lai, S.H. Han Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage Hepatology 51 2010 1185 1189
60. C.L. Lai, M.F. Yuen The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points Ann Intern Med 147 2007 58 61
61. D. Ratnam, A. Dev, T. Nguyen The efficacy and tolerability of pegylated interferon-alpha-2a in chronic hepatitis B: a multicenter clinical experience J Gastroenterol Hepatol 2011 Dec 14 [Epub ahead of print]
62. M.C. Tsai, C.M. Lee, K.W. Chiu A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice J Antimicrob Chemother 67 2012 696 699
63. W. Chotiyaputta, C. Peterson, F.A. Ditah Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B J Hepatol 54 2011 12 18
64. C. Hongthanakorn, W. Chotiyaputta, K. Oberhelman Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice Hepatology 53 2011 1854 1863
65. C.A. Wu, S.Y. Lin, S.K. So Hepatitis B and liver cancer knowledge and preventive practices among Asian Americans in the San Francisco Bay Area, California Asian Pac J Cancer Prev 8 2007 127 134
66. G.X. Ma, S.E. Shive, C.Y. Fang Knowledge, attitudes, and behaviors of hepatitis B screening and vaccination and liver cancer risks among Vietnamese Americans J Health Care Poor Underserved 18 2007 62 73
67. G.X. Ma, C.Y. Fang, S.E. Shive Risk perceptions and barriers to Hepatitis B screening and vaccination among Vietnamese immigrants J Immigr Minor Health 9 2007 213 220
68. H. Pollack, K. Wan, T. Miyoshi Management of chronic hepatitis B virus (HBV) infection by primary care physicians in urban hospital and clinics in New York City Hepatology 46 Suppl 2007 676A [abstract 984]
69. S.D. Chao, E.T. Chang, P.V. Le The Jade Ribbon Campaign: a model program for community outreach and education to prevent liver cancer in Asian Americans J Immigr Minor Health 11 2009 281 290
70. M. Dulay, A. Baron, C. Lai Are primary care clinicians knowledgeable about screening for chronic hepatitis B infection? Presented at the 30th annual meeting of the Society of General Internal Medicine (SGIM) J Gen Intern Med 22 Suppl 1 2007 747 753
71. J.M. Ferrante, D.G. Winston, P.H. Chen Family physicians' knowledge and screening of chronic hepatitis and liver cancer Fam Med 40 2008 345 351
72. C. Cohen, S.D. Holmberg, B.J. McMahon Is chronic hepatitis B being undertreated in the United States? J Viral Hepat 18 2011 377 383
73. S.T. Wiersma, B. McMahon, J.M. Pawlotsky Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus Liver Int 31 2011 755 761
74. C.T. Wai, J.K. Greenson, R.J. Fontana A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C Hepatology 38 2003 518 526